SCHEMBL8620951

SCHEMBL8620951

CC(=O)N1CCc2cc(Br)c(CCC3CCCCN3C)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
HTR2A P28223 3/20 0.40
DRD2 P14416 2/20 0.40
HTR7 P34969 2/20 0.40
HTR6 P50406 2/20 0.40
POLB P06746 1/20 0.40
DRD1 P21728 1/20 0.40
HRH2 P25021 1/20 0.40
HTR2C P28335 1/20 0.40
OPRK1 P41145 1/20 0.40
HTR2B P41595 1/20 0.40
KCNH2 Q12809 1/20 0.40
SLC6A4 P31645 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RECQL P46063 1/20 0.39
NOTUM Q6P988 5/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8612657 0.81 NOTUM (0.47) TSHRPOLBALDH1A1HPGDKDM4E
SCHEMBL8658481 0.76 HTR1A (0.55) HTR2APOLBDRD1HRH2HTR2C
SCHEMBL8617695 0.75 NOTUM (0.43) ALDH1A1HPGDKDM4ERECQLNOTUM
SCHEMBL8616789 0.73 SLC6A4 (0.43) HTR2ADRD2HTR7HTR6DRD1
SCHEMBL21469289 0.72 NOTUM (0.54) TSHRPOLBALDH1A1KDM4ENOTUM
SCHEMBL8148793 0.68 NOTUM (0.54) ALDH1A1HPGDKDM4ERECQLNOTUM
SCHEMBL21469189 0.68 NOTUM (0.58) HTR2AHTR2CALDH1A1HPGDKDM4E
SCHEMBL8615022 0.68 ALDH1A1 (0.47) HTR2ADRD1HRH2HTR2COPRK1
SCHEMBL15640026 0.67 NOTUM (0.59) ALDH1A1HPGDKDM4ENOTUMKMT2A
SCHEMBL8129693 0.67 SLC2A1 (0.49) TSHRALDH1A1HPGDKDM4ENOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1998050346-A2 ACETAMIDE AND UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CNS DISORDERS SMITHKLINE BEECHAM PLC (GB) 1998-11-12 WO disclosed